WallStSmart

AstraZeneca PLC (AZN)vsSHL Telemedicine Ltd American Depositary Shares (SHLT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

AstraZeneca PLC generates 104905% more annual revenue ($58.74B vs $55.94M). AZN leads profitability with a 17.4% profit margin vs -15.8%. AZN earns a higher WallStSmart Score of 64/100 (C+).

AZN

Buy

64

out of 100

Grade: C+

Growth: 6.7Profit: 8.0Value: 5.3Quality: 5.0
Piotroski: 6/9Altman Z: 1.48

SHLT

Avoid

32

out of 100

Grade: F

Growth: 3.3Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AZNUndervalued (+4.1%)

Margin of Safety

+4.1%

Fair Value

$214.51

Current Price

$187.37

$27.14 discount

UndervaluedFair: $214.51Overvalued
SHLTUndervalued (+86.0%)

Margin of Safety

+86.0%

Fair Value

$14.64

Current Price

$2.05

$12.59 discount

UndervaluedFair: $14.64Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AZN5 strengths · Avg: 9.0/10
Market CapQuality
$287.11B10/10

Mega-cap, among the largest globally

EPS GrowthGrowth
53.9%10/10

Earnings expanding 53.9% YoY

Return on EquityProfitability
22.8%9/10

Every $100 of equity generates 23 in profit

Operating MarginProfitability
21.6%8/10

Strong operational efficiency at 21.6%

Free Cash FlowQuality
$1.38B8/10

Generating 1.4B in free cash flow

SHLT1 strengths · Avg: 10.0/10
Price/BookValuation
0.5x10/10

Reasonable price relative to book value

Areas to Watch

AZN4 concerns · Avg: 3.5/10
PEG RatioValuation
1.544/10

Expensive relative to growth rate

P/E RatioValuation
27.9x4/10

Moderate valuation

Revenue GrowthGrowth
4.1%4/10

4.1% revenue growth

Altman Z-ScoreHealth
1.482/10

Distress zone — elevated risk

SHLT4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$39.26M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-11.5%2/10

ROE of -11.5% — below average capital efficiency

Revenue GrowthGrowth
-3.9%2/10

Revenue declined 3.9%

Comparative Analysis Report

WallStSmart Research

Bull Case : AZN

The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.

Bull Case : SHLT

The strongest argument for SHLT centers on Price/Book.

Bear Case : AZN

The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.

Bear Case : SHLT

The primary concerns for SHLT are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

AZN profiles as a value stock while SHLT is a turnaround play — different risk/reward profiles.

SHLT carries more volatility with a beta of 0.29 — expect wider price swings.

AZN is growing revenue faster at 4.1% — sustainability is the question.

AZN generates stronger free cash flow (1.4B), providing more financial flexibility.

Bottom Line

AZN scores higher overall (64/100 vs 32/100), backed by strong 17.4% margins. SHLT offers better value entry with a 86.0% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AstraZeneca PLC

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.

SHL Telemedicine Ltd American Depositary Shares

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

SHL Telemedicine Ltd., develops and markets personal telemedicine solutions in Israel, Europe, and internationally. The company is headquartered in Tel Aviv, Israel.

Want to dig deeper into these stocks?